Study feasibility outcomes (formulae detailed summary in Additional file 1) | |
• Proportion of patients randomised outside of weekday daytime hours). • Device deployment time- measured as the pause in chest compressions associated with device deployment. • Proportion of patients/consultees providing agreement to ongoing study participation. • Success of study blinding procedures. • Proportion of patients with complete follow-up data. • Proportion of patients with analysable chest compression quality data. | |
Patient outcomes | |
• Return of spontaneous circulation- defined as the return of a spontaneous circulation for at least twenty minutes. • Duration of critical care and hospital stay. • Survival- measured at hospital discharge, 30-days, and 6-months. • Quality of life- measured using EQ-5D-5 L (EuroQOL- 5 dimensions- 5 levels) and SF-12 (12-item short form survey) questionnaires at hospital discharge and 6-months. • Good neurological outcome measured using cerebral performance category (CPC) at discharge and the modified Rankin score (mRS) at discharge and at six-months. Good neurological outcome will be defined as a CPC of 1 or 2 or return to baseline (pre-admission) CPC, or mRS of 0–3 or return to baseline (pre-admission) mRS. | |
Process outcomes | |
• Cardiopulmonary resuscitation (CPR) quality (chest compression rate, chest compression depth, flow-fraction, pre-shock pause, post-shock pause, peri-shock pause). | |
Safety outcomes | |
• Device related adverse events |